Adoptive Cell Therapy against Cancers

Dear Colleagues,

Adoptive cell therapy (ACT), especially, chimeric antigen receptor (CAR) T cell therapy, is rapidly growing and have revolutionized the field of immunotherapy for cancer, showing promise in the treatment of cancer patients, leading to durable responses and, in some cases, cure. However, many challenges limit the therapeutic efficacy of ACT in solid tumors and hematological malignancies. Barriers to effective ACT include time-consuming and lab-intensive manufacturing, complex logistics, severe life-threatening toxicities, modest anti-tumor activity, antigen escape, restricted trafficking, and limited tumor infiltration, and so on. To overcome these hurdles, several strategies, from screening the best starting material, developing novel CAR or TCR structures and improving the manufacturing process up to combining ACT with other anti-tumor agents, could be considered to optimize the clinical efficacy of ACT.

This Special Issue aims to cover recent advances in adoptive cell therapy including manufacturing, method validation for product specification, logistics study, novel CAR design, combination therapy and clinical trials and therefore seeks for review or original manuscripts addressing one of the aforementioned (or related) topics.

We look forward to receiving your contributions.

Dr. Lei Wang
Dr. Sanmei Wang
Dr. Wenjie Gong
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.